MEDI Overview

Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.

Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.

Eli Lilly's Influence on Healthcare ETFs: Eli Lilly has become a significant driver in the pharmaceutical ETF market, with around 15 ETFs allocating double-digit weights to the company, making it a key player in healthcare fund performance.

Strong Q3 Performance: In Q3, Eli Lilly reported a 54% year-over-year revenue increase, surpassing Wall Street expectations, and raised its full-year sales and EPS guidance, solidifying its status as a growth engine in the sector.

Major ETF Allocations: Leading ETFs like iShares US Pharmaceuticals ETF and VanEck Pharmaceutical ETF have substantial allocations to Lilly, with weights of 26.9% and 24.1% respectively, indicating a strong reliance on the stock for performance.

Concerns Over Concentration: While Eli Lilly's growth is beneficial for investors, there are concerns about the potential over-dependence of ETFs on a single stock, as Lilly's performance continues to significantly impact the broader pharmaceutical ETF market.

Biotech Sector Recovery: Biotech stocks are rebounding after a four-year downturn, with the SPDR S&P Biotech ETF (XBI) rising 25% year-to-date as of October 31.

Performance Comparison: The biotech sector's performance has outpaced the S&P 500 by 9 percentage points during the same period.

Future Outlook: Analysts believe that the strength of the biotech sector is likely to persist, indicating potential opportunities for investors.

Investment Timing: Experts suggest that it is not too late for investors to enter the biotech market.

Berkshire Hathaway Investment: Berkshire Hathaway acquired over 5 million shares of UnitedHealth (UNH) worth $1.57 billion, boosting UNH's stock price by 12% on August 15, 2025, amidst other investments from notable hedge funds.

Earnings and Projections: UnitedHealth's second-quarter earnings fell short of estimates due to high operating costs, with projected revenues for 2025 now between $445.5 billion and $448 billion, while adjusted net EPS is expected to be at least $16, down from previous guidance.

Stock Performance: UNH shares have significantly underperformed, falling 47.5% over the past year, with a current valuation of 10.83X forward P/E, leading to concerns among investors despite recent acquisitions strengthening its market presence.

Investment Recommendations: Analysts suggest investing in UNH-heavy ETFs to mitigate company-specific risks, with various price targets set for UNH shares ranging from $198 to $440, reflecting mixed sentiments about the stock's future performance.

Warren Buffett's Investment Moves: Berkshire Hathaway disclosed new investments, including over 5 million shares in UnitedHealth Group valued at $1.6 billion, which led to an 11% stock increase.

Focus on Homebuilders: Buffett has increased stakes in homebuilding companies like Lennar and D.R. Horton, indicating confidence in the housing market amid easing mortgage rates.

Consumer Staples Investments: Buffett expanded his positions in food and beverage companies such as Constellation Brands and Domino’s Pizza, reflecting a strategy focused on non-cyclical sectors that perform well during economic slowdowns.

Reduction in Apple and Bank of America Stakes: Berkshire Hathaway has significantly reduced its holdings in Apple by 69% and Bank of America by selling 26 million shares, continuing a trend of trimming large positions amidst changing market dynamics.

UnitedHealth Group Stock Performance: UnitedHealth Group's stock has plummeted over 50% year-to-date due to weak Q1 earnings and a lowered full-year outlook, prompting investors to consider ETFs like Harbor Health Care ETF (MEDI) and T. Rowe Price Health Care ETF (TMED) for diversified exposure.

ETF Details and Ratings: The MEDI ETF has a Strong Buy consensus with a 42.79% upside potential, while the TMED ETF holds a Moderate Buy rating with a 41.31% upside potential; both provide indirect exposure to UNH stock, reducing investment risk.